Loading market data...
Thu, 29 Oct 2026
05:14:15 am
Thu, 29 Oct 2026
05:14:15 am
Rudransh Sangwan
Published at: October 29, 2026, 3:27 AM
Synopsis
Piramal Pharma shares surged 16.04% after Q2 FY27 profit reached ₹5 crore and revenue rose 28%. Choice Institutional Equities set a ₹250 target.
Piramal Pharma shares jumped 16.04% to ₹230.60 on October 28, 2026, after the company reported a return to profitability in Q2 FY27. Strong revenue growth also prompted Choice Institutional Equities to upgrade the stock and set a ₹250 target price.
Piramal Pharma reported a consolidated net profit of ₹5 crore, compared with a net loss of ₹99.22 crore in the same quarter last year.
Revenue rose 28% year-on-year to ₹2,617 crore, beating the estimated ₹2,327 crore.
| Financial Metric | Q2 FY27 | Q2 FY26 |
|---|---|---|
| Net Profit | ₹5 crore | -₹99.22 crore |
| Revenue | ₹2,617 crore | — |
| Total Expenses | ₹2,589.10 crore | ₹2,170.29 crore |
The stock touched an intraday high of ₹235.64 before closing at ₹230.60.
| Metric | Performance |
|---|---|
| One-day return | +16.04% |
| October return | Nearly +13% |
| Year-to-date return | +35.74% |
| One-year return | +14.10% |
| Three-year return | +149.30% |
Choice Institutional Equities upgraded Piramal Pharma to ‘Add’ and set a target price of ₹250, implying approximately 8.4% upside from the closing price of ₹230.60.
Potential growth drivers include CDMO business momentum, complex product launches, established brands, e-commerce sales and improving biopharma funding.
Investors will monitor whether Piramal Pharma can sustain revenue growth and profitability in the coming quarters. The brokerage target is an estimate, not a guaranteed return.
Disclaimer: This article is for informational and educational purposes only and is not investment advice. Conduct independent research before making investment decisions.
Piramal Pharma shares surged after the company reported a surprise consolidated net profit for Q2 FY27, beating market expectations for another quarterly loss. Strong revenue growth and better-than-expected results helped drive investor interest.
Piramal Pharma reported a consolidated net profit of ₹5 crore for the July-September 2026 quarter, compared with a loss of ₹99.22 crore a year earlier. Revenue from operations rose 28% year-on-year to approximately ₹2,617 crore.
Piramal Pharma shares closed at ₹230.60 on October 28, 2026, gaining 16.04% during the session. The stock reached an intraday high of ₹235.64, its highest level in 18 months, according to the reported market data.
Choice Institutional Equities upgraded Piramal Pharma to Add and set a target price of ₹250 per share. Based on the October 28 closing price of ₹230.60, this implied potential upside of approximately 8.4%, excluding costs and other factors.
The company benefited from revenue growth that outpaced the increase in expenses. Higher sales, improving operating performance and contributions from its contract development and manufacturing organisation (CDMO) business supported the quarterly recovery.
Potential growth drivers include the CDMO business, complex product launches, premiumisation of brands, growth in power brands and e-commerce, and improving biopharma funding that could support order inflows.
Choice Institutional Equities expects the company's recovery to strengthen in the second half of FY27, supported by revenue growth and operating leverage. Actual performance will depend on order inflows, product launches, margins and business conditions.
The strong results and brokerage upgrade may support investor sentiment, but they do not guarantee further gains. Investors should assess the company's earnings sustainability, margins, valuation and business outlook, while remembering that the ₹250 target is a brokerage estimate rather than a guaranteed price.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Jubilant Ingrevia shares fell 6.13% to ₹593.60 despite East Bridge Capital Master Fund I buying 9.21 lakh shares worth ₹55.46 crore, acquiring a 0.
Titagarh Rail Systems received an additional ₹1,716.90 crore Ministry of Railways order, raising the amended contract value to ₹10,404.10 crore.
Everest Group Q3 2026 results show net operating EPS of $7.62, below estimates, as net premiums earned fell 18.
Force Motors Q2 FY27 results show revenue rising 40.5% to ₹2,924.5 crore, while standalone net profit falls 16.6% to ₹291.
Northwest Pipe Q3 results show EPS of $1.86, beating estimates by 12.73%, while sales rose 18.75% year-on-year to $179.39 million.
